Price T Rowe Associates Inc Novo Cure LTD Transaction History

Price T Rowe Associates Inc

  • $812 Billion
  • Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Price T Rowe Associates Inc holds 482,034 shares of NVCR stock, worth $8.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
482,034
Previous 1,683,818 71.37%
Holding current value
$8.94 Million
Previous $50.2 Million 82.88%
% of portfolio
0.0%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
SELL
$17.82 - $30.19 $21.4 Million - $36.3 Million
-1,201,784 Reduced 71.37%
482,034 $8.59 Million
Q4 2024

Feb 14, 2025
SELL
$14.54 - $33.41 $9.28 Million - $21.3 Million
-638,378 Reduced 27.49%
1,683,818 $50.2 Million
Q3 2024

Nov 14, 2024
BUY
$15.61 - $23.34 $2.59 Million - $3.88 Million
166,175 Added 7.71%
2,322,196 $36.3 Million
Q2 2024

Aug 14, 2024
SELL
$11.83 - $24.05 $2.64 Million - $5.36 Million
-222,919 Reduced 9.37%
2,156,021 $36.9 Million
Q1 2024

May 15, 2024
BUY
$12.42 - $17.29 $1.56 Million - $2.17 Million
125,715 Added 5.58%
2,378,940 $37.2 Million
Q4 2023

Feb 14, 2024
SELL
$11.13 - $15.78 $1.24 Million - $1.76 Million
-111,234 Reduced 4.7%
2,253,225 $33.6 Million
Q3 2023

Nov 14, 2023
SELL
$16.15 - $42.35 $2.92 Million - $7.67 Million
-181,006 Reduced 7.11%
2,364,459 $38.2 Million
Q2 2023

Aug 14, 2023
SELL
$40.29 - $82.51 $4.44 Million - $9.09 Million
-110,221 Reduced 4.15%
2,545,465 $106 Million
Q1 2023

May 15, 2023
BUY
$56.44 - $118.81 $27.5 Million - $57.9 Million
487,255 Added 22.47%
2,655,686 $160 Million
Q4 2022

Feb 14, 2023
SELL
$63.98 - $85.37 $13 Million - $17.4 Million
-203,555 Reduced 8.58%
2,168,431 $159 Million
Q3 2022

Nov 14, 2022
BUY
$67.99 - $89.57 $2.76 Million - $3.64 Million
40,619 Added 1.74%
2,371,986 $180 Million
Q2 2022

Aug 15, 2022
BUY
$56.6 - $89.9 $12.4 Million - $19.6 Million
218,216 Added 10.33%
2,331,367 $162 Million
Q1 2022

May 16, 2022
BUY
$60.15 - $84.52 $37.7 Million - $53 Million
626,983 Added 42.19%
2,113,151 $175 Million
Q4 2021

Feb 14, 2022
BUY
$75.08 - $121.99 $4.03 Million - $6.55 Million
53,701 Added 3.75%
1,486,168 $112 Million
Q3 2021

Nov 15, 2021
SELL
$116.17 - $194.55 $15.9 Million - $26.7 Million
-137,018 Reduced 8.73%
1,432,467 $166 Million
Q2 2021

Aug 16, 2021
BUY
$130.4 - $225.58 $44.6 Million - $77.1 Million
341,783 Added 27.84%
1,569,485 $348 Million
Q1 2021

May 17, 2021
SELL
$124.11 - $190.17 $1.3 Million - $2 Million
-10,502 Reduced 0.85%
1,227,702 $162 Million
Q4 2020

Feb 16, 2021
BUY
$112.16 - $174.14 $139 Million - $216 Million
1,238,204 New
1,238,204 $214 Million

Others Institutions Holding NVCR

# of Institutions
266
Shares Held
79.4M
Call Options Held
970K
Put Options Held
118K
View Full List

About NovoCure Ltd

NVCR Quotes by TradingView
  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.95B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email